NIPD on CFTC for Triplet Repeat Diseases (DIACCIMEX)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03087526|
Recruitment Status : Recruiting
First Posted : March 22, 2017
Last Update Posted : June 5, 2018
|Condition or disease||Intervention/treatment||Phase|
|Non Invasive Prenatal Diagnosis||Genetic: Non invasive prenatal diagnosis||Not Applicable|
Non Invasive Prenatal Diagnosis (NIPD), based on the analysis of circulating cell-free fetal DNA (cff-DNA) is very promising for early diagnosis of monogenic diseases. Such an approach is a safer alternative to invasive methods of prenatal testing (amniocentesis or choriocentesis) which entails a significant risk of miscarriage (0.5%-1%). However, technical issues related to the characteristics of cff-DNA remain and do not allow the search of all the mutations, in particular triplet expansion mutations which concern rare and incurable diseases (Huntington's disease, Steinert Myotonic dystrophy, Fragile X syndrome, SCA1, 2, 3). Indeed, the strong fragmentation and the short size of cff-DNA (143 bp) do not allow direct detection of these mutations. However, Prenatal Diagnosis (PND) requests for this group of pathologies represent the second most frequent PND indication at the national level after cystic fibrosis (ABM 2013). An alternative approach is to perform analysis on circulating fetal trophoblastic cells (CFTC) from maternal blood. Several methods have been used to isolate CFTCs from maternal blood. However, to date, no test is reliable enough for a routine application to replace invasive protocols. Recently, new enrichment systems have been optimized for circulating tumor cells (CTCs) as a liquid biopsy of cancer. Some of these new technologies can be easily applied to the isolation and characterization of CFTCs. The objective of this study is to complete our NIPD services by developing an approach on CFTC adapted to the analysis of triplet repeat diseases, which cannot be performed on cff-DNA.
It is a multicenter, prospective study for performance evaluation of a diagnostic method. The subjects included will be pregnant women between 9 and 34 weeks of gestation and their partner (future fathers). Pregnant woman and future father genotypes (sick or healthy) are known for one of the following diseases: Huntington's disease, Steinert's myotonic dystrophy, fragile X and spinocerebellar ataxias types 1, 2 or 3. The main objective is achieved by the agreement between gold standard (PND by amniocentesis or choriocentesis) and NIPD results for each pregnant woman participating in the study (the absence or presence of the mutated allele).
The couple inclusion will take place in one of the participating medical genetic centers during genetic counseling consultation for a pregnancy at risk for one of the pathologies mentioned above.
During this visit, the pregnant woman's blood sample (blood sample taken on 3 x 10 ml BCT and 5 ml on EDTA) and the future father (5 ml on EDTA) will be carried out. The duration of inclusion is the time of the visit. Blood collection of pregnant women on cell-free DNA "Blood Collection Tubes" (BCT) to screen CFTCs will be addressed to the Human Rare Circulating Cells Laboratory (LCCRH). The molecular analysis of the CFTC isolated by the LCCRH as well as the genomic DNA extraction and analysis (from the 5 ml of blood on EDTA) of the couple will be carried out by the Laboratory of Molecular Genetics (LGM) located in the same Building (IURC - Montpellier University Hospital).
The analysis performed on a simple maternal blood test will allow to determine whether the future child is affected or not by the inherited disease. With this new NIPD approach, there could be a 50% decrease in the use of the invasive method for PND. This analysis can be offered to women carrying foetuses at risk for triplet repeat diseases. Finally, this approach can be applied to any monogenic diseases by CFTCs isolation automation from maternal blood.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Non Invasive Prenatal Diagnosis on Isolated Circulating Fetal Trophoblastic Cells (CFTC) for Triplet Repeat Diseases|
|Actual Study Start Date :||June 12, 2017|
|Estimated Primary Completion Date :||December 12, 2019|
|Estimated Study Completion Date :||April 30, 2020|
Experimental: Couple at risk of transmitting a triplet-repeat disease
Expectant couple (pregnant woman between 9 and 34 weeks of gestation and her spouse) at risk of transmitting a triplet-repeat related genetic disease among Huntington disease, Myotonic Dystrophy type 1, Fragile X syndrome, Spinocerebellar Ataxia type 1, Spinocerebellar Ataxia type 2, Spinocerebellar Ataxia type 3
Genetic: Non invasive prenatal diagnosis
Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
- Concordance rate between cell-based genetic non invasive prenatal test and gold standard prenatal test (choriocentesis or amniocentesis). [ Time Frame: 30 months ]Analysis of the concordance of the prenatal results obtained by our new NIPD (Non-Invasive Prenatal Diagnosis) approach and those blindly obtained during the gold-standard prenatal genetic test will be carried out for each pregnant woman participating in the study.
- Non Invasive Prenatal Diagnostic test failure rate. [ Time Frame: 30 months ]Count of the women enrolled for whom NIPD test will be inconclusive (because of insufficient circulating fetal cells isolation or allele drop out making accurate haplotyping impossible).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03087526
|Contact: Marie Claire VINCENT, PhD-PharmaD||411759879 ext firstname.lastname@example.org|
|Contact: Claire GUISSART||411759879 ext email@example.com|
|Bordeaux, France, 33076|
|Contact: Cyrile GOIZET, MD-PHD +335 56 79 59 52 firstname.lastname@example.org|
|Montpellier, France, 34295|
|Contact: Christine COUBES, MD 334 67 33 65 64 email@example.com|
|Nice, France, 06202|
|Contact: Cécile ROUZIER, MD +334.92.03.62.43 firstname.lastname@example.org|
|Nîmes, France, 30029|
|Contact: Philippe KHAU VAN KIEN, MD philippe.KHAUVANKIEN@chu-nimes.fr|
|Rennes, France, 35203|
|Contact: Mélanie FRADIN, MD +3220.127.116.11.51 Melanie.FRADIN@chu-rennes.fr|
|CH Saint Brieuc||Recruiting|
|Saint Brieuc, France, 22027|
|Contact: Mélanie FRADIN, MD +332.99.01.72.68|
|Schiltigheim, France, 67303|
|Contact: Romain FAVRE, MD-PHD +333 69 55 34 15 email@example.com|
|Toulouse, France, 31059|
|Contact: Patrick CALVAS, MD-PHD +335 61 77 90 79 firstname.lastname@example.org|
|Principal Investigator:||Marie Claire VINCENT, PhD-PharmaD||University Hospital, Montpellier|